Features | Partner Sites | Information | LinkXpress
Sign In
SIEMENS DIAGNOSTICS

Prostate Cancer Genetic Tests Predicts Prognosis

By Labmedica International staff writers
Posted on 21 Jan 2013
Diagnostic and prognostic genetic tests have been developed to better predict prostate cancer survival outcomes and distinguish clinically relevant cancers.

The diagnostic test distinguished patients with clinically relevant prostate cancer from normal prostate in men with elevated prostate-specific antigen (PSA) levels, and prognostic tests separate out men who died of prostate cancer versus those who lived.

Scientists at the Kimmel Cancer Center (Philadelphia, PA, USA) performed a retrospective analysis of over 350 patients using an oncogene-specific prostate cancer molecular signature, based on studies carried out in mice. They worked with three oncogenes previously associated with poorer outcomes in prostate cancer: avian myelocytomatosis viral oncogene homolog (c-Myc), Harvey rat sarcoma viral oncogene homolog (Ha-Ras), and sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (v-Src).

Canonical analysis was performed using the c-Myc-specific genes that were also found to be differentially expressed between tumor and normal samples in two human prostate datasets. The first canonical variable, resulting from this analysis, was used to discriminate tumor from normal samples in each human prostate dataset. The oncogene-specific prostate cancer molecular signatures were repeated and validated in distinct populations of patients as a prognostic and diagnostic test for human prostate cancer. The c-Myc gene copy number is increased in up to 30% of cases at the preneoplastic stage in patients with prostatic intraepithelial neoplasia. Specifically the tests identified men whose outcome was fatal on average after 30 months.

Richard G. Pestell, MD, PhD, the senior investigator of the study said, "This oncogene signature shows further value over current biomarkers of prediction and outcomes. Such a signature and cell line may also enable the identification of targets for therapies to better treat prostate cancer, which takes the lives of over 27,000 men a year. With this new oncogene-specific prostate cancer molecular signature, we have a valuable prognostic and diagnostic resource that could help change the way we manage and treat prostate cancer." The study was published online on November 30, 2012, in the journal Cancer Research.

Related Links:
Kimmel Cancer Center




comments powered by Disqus

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.